Skip to content

Savara SVRA Investment Proceeds

Investment Proceeds at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$93.97M+422%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$96M+194%
TRV
Trevi Therapeutics, Inc.TRVI
$25.55M+45.2%
United Therapeutics logo
United TherapeuticsUTHR
$1.31B
TG Therapeutics logo
TG TherapeuticsTGTX
$11.25M-86.0%
Insmed logo
InsmedINSM

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.24B+247%
Enterprise value$1.23B+235%
P/S4,808.2×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's investment proceeds?
Savara (SVRA) reported investment proceeds of $13.13M in Q1 2026.
How has Savara's investment proceeds changed year-over-year?
Savara's investment proceeds decreased by 70.4% year-over-year, from $44.4M to $13.13M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.